The Many Faces of Interleukin-6: The Role of IL-6 in Inflammation, Vasculopathy, and Fibrosis in Systemic Sclerosis PDF Print E-mail
Wednesday, 21 March 2012 20:39
Theresa C. Barnes,Marina E. Anderson, and Robert J.Moots
Received 1 June 2011; Accepted 21 July 2011

Systemic sclerosis (SSc) is a connective tissue disease characterised by fibrosis, vasculopathy, and immunological abnormalities. Over recent years, it has become clear that inflammation plays a crucial role in mediating the pathophysiological process underlying SSc, especially early in the disease. Endothelial cell activation and dysfunction are central to the disease pathogenesis, may be driven by a proinflammatory environment, and may result in the generation of a profibrotic phenotype.

Interleukin-6 (IL-6) is a pleiotropic cytokine. In addition to its role in the acute phase response, IL-6 has diverse roles in driving chronic inflammation, autoimmunity, endothelial cell dysfunction, and fibrogenesis. Therefore, it is currently attracting a great deal of interest in the rheumatology community as a potential therapeutic agent in SSc, a disease which at present lacks treatments directed at the underlying pathogenesis.

Recent evidence has suggested that IL-6 may play important roles in endothelial cell dysfunction and fibrogenesis in this disease, and clinical trials are currently being designed to further explore whether Tocilizumab, a monoclonal antibody directed against the IL-6 receptor, may be of therapeutic benefit to patients with SSc.

Continue reading the full review article, by downloading it from the link provided below.

 
More articles :

» New Biomarker Predicts Poor Outcomes in Scleroderma

A novel biomarker may aid in establishing the prognosis of Systemic Sclerosis (Scleroderma), and particularly in predicting the most common lethal complications, an international group of researchers reported.Patients with Systemic Sclerosis who had...

» Study Indicates Scleroderma Mortality Rates Being Underestimated

patients have a significantly reduced life expectancy that is most likely being underestimated, delegates have heard. Most studies on scleroderma survival are based on prevalent cohorts, where no limit is placed on disease duration at the time of...

» Rheumatic Autoimmune Diseases: A Local Perspective

Arguably one of the more exciting presentations delivered at the recently concluded , local Rheumatologist Dr. Haramnauth Dyaanand of the Gulf View Medical Centre, delved excitedly into the local context for autoimmune diseases. Starting off largely...

» Tyrosine Kinase Inhibitors in the Treatment of Systemic Sclerosis: The Difficulty in Interpreting Proof-of-Concept Studies

Jessica Gordon and Robert SpieraReceived 1 June 2011; Revised 2 August 2011; Accepted 2 August 2011Systemic sclerosis (SSc) is a heterogeneous, multisystem disorder characterized by vasculopathy, fibrosis, and autoimmunity in the context of both...

» Targeted Therapy for Systemic Sclerosis: How Close are We?

Manuel Ramos-Casals; Vicent Fonollosa-Pla; Pilar Brito-Zerón; Antoni Sisó-AlmirallPosted: 09/14/2010; Nat Rev Rheumatol. 2010;6(5):269-278. © 2010 Nature Publishing GroupDespite recent etiopathogenetic advances, systemic sclerosis continues to be...

» Unite Against Scleroderma

On May 1st 2011, the would be holding its first annual "Unite Against Scleroderma" Walk around the Queen's Park Savannah, Port Of Spain. It is our aim to help raise awareness of this rare autoimmune disease and the funding needed to aid those who...